- 1 The isolated effect of age on the risk of COVID-19 severe outcomes: a systematic review with meta-
- 2 analysis

- 3 Karla Romero Starke^{1,2}, David Reissig¹, Gabriela Petereit-Haack³, Stefanie Schmauder¹, Albert
- 4 Nienhaus^{4,5}, Andreas Seidler¹
- 6 Institute and Policlinic of Occupational and Social Medicine (IPAS), Faculty of Medicine Carl Gustav
- 7 Carus, Technische Universität Dresden, 01307 Dresden, Germany
- 8 Institute of Sociology, Faculty of Behavioral and Social Sciences, Technische Universität Chemnitz,
- 9 Thüringer Weg 9, 09126 Chemnitz, Germany
- ³ Division of Occupational Health, Department of Occupational Safety, Regional Government of South
- Hesse, 65197 Wiesbaden, Germany
- 12 ⁴ Department of Occupational Medicine, Toxic Substances and Health Research, Institution for
- 13 Statutory Social Accident Insurance and Prevention in the Health Care and Welfare Services (BGW),
- 14 22089 Hamburg, Germany
- 15 Competence Centre for Epidemiology and Health Services Research for Healthcare Professionals
- 16 (CVcare), Institute for Health Service Research in Dermatology and Nursing (IVDP), University Medical
- 17 Centre Hamburg-Eppendorf (UKE), 20251 Hamburg, Germany

19 Abstract 20 Introduction 21 Increased age has been reported to be a factor for COVID-19 severe outcomes. However, many 22 studies do not consider the age-dependency of comorbidities, which influence the course of disease. 23 Protection strategies often target individuals after a certain age, which may not necessarily be 24 evidence-based. The aim of this review was to quantify the isolated effect of age on hospitalization, 25 admission to ICU, mechanical ventilation, and death. 26 Methods 27 This review was based on an umbrella review, in which Pubmed, Embase, and pre-print databases 28 were searched on December 10, 2020 for relevant reviews on COVID-19 disease severity. Two 29 independent reviewers evaluated the primary studies using predefined inclusion and exclusion 30 criteria. The results were extracted, and each study was assessed for risk of bias. The isolated effect 31 of age was estimated by meta-analysis, and the quality of evidence was assessed using GRADE. 32 Results 33 Seventy studies met our inclusion criteria (case mortality n=14, in-hospital mortality n=44, 34 hospitalization n=16, admission to ICU n=12, mechanical ventilation n=7). The risk of in-hospital and 35 case mortality increased per age year by 5.7% and 7.4%, respectively (Effect Size (ES) in-hospital 36 mortality=1.057, 95% CI:1.038-1.054; ES case mortality=1.074, 95% CI:1.061-1.087), while the risk of 37 hospitalization increased by 3.4% per age year (ES=1.034, 95% CI:1.021-1.048). No increased risk was 38 observed for ICU admission and intubation by age year. There was no evidence of a specific age 39 threshold at which the risk accelerates considerably. The confidence of evidence was high for 40 mortality and hospitalization.

Conclusions

Our results show a best-possible quantification of the increase in COVID-19 disease severity due to
age. Rather than implementing age thresholds, prevention programs should consider the continuous
increase in risk. There is a need for continuous, high-quality research and "living" reviews to evaluate

the evidence throughout the pandemic, as results may change due to varying circumstances.

45

What is already known?

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

Increasing age and comorbidities are risk factors for COVID-19 severe outcomes, such as
hospitalization and mortality. However, comorbidities such as diabetes, cardiovascular
disease, chronic pulmonary diseases increase with age, and the isolated effect of age on
COVID-19 disease severity is not known.

What are the new findings?

- The risk of COVID-19 disease severity due to the isolated effect of age increases by age year
 and no specific age threshold was observed.
- A best possible quantification of the increase in risk of COVID-19 severe outcomes due to age has been done.

What do the new findings imply?

- Any workplace restrictions targeting a particular older age group are rather arbitrary, and may contribute to ageism in the society.
- If scores are to be built to assess an individual's risk for COVID-19 severe outcomes in workplace settings, these should be based on per-age increases.

1. Introduction

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

Since identified in Wuhan, China in December 2019 (1), COVID-19 has caused more than 3.4 million deaths worldwide (2). Early on, the increase COVID-19 adverse outcomes in the older population was observed (3-6). Chronic diseases, which increase with age, are also established risk factors for COVID-19 disease severity (7, 8). However, age and age-related risk factors, are often not de-coupled in studies (9). Since mortality rates are often presented by age groups (10), prevention strategies targeting older age groups in the workplace were started. After the first wave, the Federal State of Lower Saxony in Germany encouraged teachers over the age of 60 years to work from home. Recently, an IKKA score was developed in Germany for workers in order to establish, among other things, age-based criteria that could decide on the admissibility of work attendance (11). The risk score was partly-based on the age group of the individual (<50 years: score=0; 50-59 years: score=4; ≥60 years: score=10). There have been discussions concluding in a consensus over the need to improve the risk score based on current evidence regarding the isolated effect of age on COVID-19 disease severity (12). In general, we should be careful to classify 60 years of age as risk persons (or any other age group starting at a particular "arbitrary" age), as this can considerably reduce the chances of older unemployed people finding a job or make them "targets" for lay offs. In mid-2020, we published a rapid review investigating the isolated effect of age on COVID-19 disease severity - that is, the direct effect of age after accounting for important age-related risk factors such as diabetes, cardiovascular disease, and chronic pulmonary disease. The result was that the effect of age was rather small (13). This review was based mainly on Chinese studies published early in the pandemic. As more studies have been published worldwide, a different picture might emerge, and it is necessary to examine the newly acquired evidence on the isolated effect of age on COVID-19 disease severity.

We aim to gather information on published studies to answer the following:

1. What is the isolated effect of age on COVID-19 disease severity (hospitalization, admission to the intensive care unit (ICU), mechanical ventilation or death due to COVID-19), after adjusting for important age-related risk factors?

2. Is there evidence of an age threshold in which the risk of COVID-19 increases rapidly?

2. Methods

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

Search, selection, and data extraction This systematic review was based on an umbrella review on pre-existing health conditions and severe COVID-19 outcomes published elsewhere (14). To summarize, on December 11, 2020 a systematic search for systematic reviews was done in PubMed and Embase, with hand searches on preprint servers (search string in supplement). The included systematic reviews investigated the association between at least one chronic health condition and a severe COVID-19 outcome, such as hospitalization, ICU admission, intubation, or death. After screening the titles and abstracts, followed by full text screening, 120 systematic reviews were included (Figure S1). Then, primary studies included in these reviews were screened. They were included in the analysis if they reported at least one quantitative measure of association in persons with pre-existing health conditions and at least one age-adjusted estimate. 160 primary studies were included in the umbrella review (Figure S2) (14). To find adequate primary studies for the purpose of our research question regarding age and COVID-19 disease severity, we excluded studies investigating special populations, such as cancer patients or persons with diabetes. Studies were included if the age effect had been adjusted for at least three of the following comorbidities: diabetes mellitus, cardiovascular disease, cancer/immunodeficiency, chronic kidney disease, chronic liver disease, and chronic pulmonary disease (see Table 1 for eligibility criteria). Two independent scientists screened the full texts of the studies. In case of

disagreement, a consensus decision was sought between both scientists. If no agreement was

achieved, the decision was made by a third reviewer.

Table 1. Eligibility criteria

	Inclusion criteria	Exclusion criteria		
Population	General population infected with COVID-19 (both sexes, all ages)	Special populations such as studying only cancer patients or persons with diabetes		
Exposure	Age, in years	All other exposures which do not include age		
Comparator/control	Age reference, in years			
Outcomes	Due to infection with COVID- 19: risk of hospitalization, admission to ICU, intubation, and death. Risks measured as hazard ratios, risk ratios, odds ratios	Other outcomes, including outcomes of composite disease severity.		
Study design	cross-sectional, case-control, and cohort studies	RCTs, qualitative studies, ecological studies, case reports, experiments, congress abstracts, posters		

Excluded are studies only reporting univariate (unadjusted) effect values of age.

Excluded are studies in which the age effect is not adjusted at least for three comorbidities listed

here: diabetes mellitus, cardiovascular disease, cancer or immunodeficiency, chronic kidney disease,

chronic liver disease, and chronic pulmonary disease.

Data extraction was done by one reviewer and checked by another one. In case of missing information, study authors were contacted. The data extraction form included information on the first author, publication year, country of origin, study population, age and sex characteristics, outcome assessment, confounders, analysis methods, and results. A protocol of the review was registered a priori with the PROSPERO database of systematic reviews (https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=220614).

Risk of Bias Assessment

We evaluated the overall risk of bias for each study as "low" or "high", and followed the procedure for assessment based on Ijaz et al. 2013 (15), with modifications (13, 16). We also considered the criteria described by SIGN (Scottish Intercollegiate Guidelines, 2012) (17) and CASP (Critical Appraisal Skills Programme) (18). We assessed eight domain: 1) recruitment procedure and follow-up 2) exposure definition and measurement, 3) outcome definition and measurement, 4) inclusion of important age-dependent risk factors, 5) analysis method, 6) chronology, 7) funding, and 8) conflict of interest. Each domain was characterized as having a low, high, or unclear risk of bias (see

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

supplementary material for a detailed description). Domains 1-5 and 6-8 were major and minor domains, respectively. A study was evaluated as having an overall low risk of bias if all major domains had a low risk of bias. Data synthesis We evaluated studies using age categories and calculated the median of each of the age categories. If lower and upper categories were open ended, we used reasonable values based on the youngest and oldest participants included. For the younger open-ended age groups, we chose a lower boundary of 18 years if the population encompassed adults only. The median value of 18 years and the upper boundary of the lower open-ended age category was estimated. For the older open-ended age groups an upper boundary of 95 years of age was chosen and a median value was similarly calculated. However, these values were also modified in a sensitivity analysis. If studies only had risks of binary categories of age, such as >60 years vs ≤60 years, they were excluded from the metaanalysis. A log-linear model and a log-cubic model was constructed weighted for variance, and the Akaike Information Criteria (AIC) for each model was evaluated. The log of the relative risk (RR) was then plotted against the age mid-points to assess linearity for the specific outcome studied, first for each individual study, and then for all studies using categorized age. We wanted to assess whether (a) there is an age threshold present at which the ln(RR) increases and (b) whether a log-linear relationship for the categorical studies would be a reasonable assumption. If a log-linear association could be assumed, a risk effect per year was obtained by using the Generalized Least Squares for trend estimation of summarized dose-response data (glst) (19). If the number of cases per age category was unknown, the risk estimate was obtained by variance-weighted least squares (vwls). If the log-linear association could be assumed, then the studies using categorical values were pooled with the ones using continuous values through a random-effects meta-analysis using the metan package (20). A similar procedure has been done before (15, 21). If two studies investigated the same population, the study with the highest quality was chosen. Odds ratios (OR) were converted to RRs using the formula proposed by Zhang and Yu 1998 (22) when the prevalence in the reference group

was greater than 10% to avoid an overestimation of the RRs.

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

We compared the pooled effects of studies using continuous values for age and those using categorical values. Heterogeneity was assessed by I² values, and publication bias was explored using Funnel plots and Egger's test (metabias) if there were at least ten studies. Stata Version 14.2 (StatCorp, College Station, TX, USA) was used. 2.4 Assessment of the quality of the total body of evidence We used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach for grading the quality of the total body of evidence (23), following the example of Hulshof et al. 2019 (24), with modifications (25). The quality of evidence was either high, moderate, or low. Since only observational studies were included, the starting level was set to "moderate". The quality was downgraded based on four factors: study limitations, indirectness, inconsistency, imprecision, and publication bias. If study findings had large effect sizes, if there were dose-response relationships, or if the presence of residual confounding was suspected (increasing the confidence in the association), the quality of evidence was upgraded. For the effect size evaluation, we considered the difference in risk due to age between a person entering adulthood (18 years) and the worldwide life expectancy (72 years) (26), a difference of 54 years. Results After reviewing the 160 included primary studies from the umbrella review (14), we included 70

studies (27-96) (Figure 1). Table S1 lists the excluded studies with reasons.




Figure 1. Selection process for primary studies from original Umbrella Review (Treskova et al. 2020)

182

183

184

Except for Gu et al. 2020 (51), a case control study, all studies were either retrospective or prospective cohort studies. Most originated from USA (34), while 14 studies came from Europe, 8

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

from Latin America (Mexico and Brazil), 10 from China, two from South Korea, and one each from South Africa and Israel. Details on study characteristics are in Table S2. In-hospital mortality Forty-four studies investigating the risk of in-hospital mortality, meaning the risk of mortality in hospitalized patients, were included. Most studies were set in Western countries, such as USA (n=21), Europe (n=13), and Latin America (n=2). Six studies were set in China, one in South Africa, and one in South Korea. Nineteen studies reported the risk of in-hospital mortality per age year, while the others used age categories to report the effect of age on risk. The results can be seen in Table S3. From the 44 studies, eight studies (28, 30, 34, 48, 64, 72, 75, 77) were assessed as having a low risk of bias. The majority had a high risk of bias because not all six age-dependent comorbidities were included in the model, while some used rough age categories in their models (greater than 10 years or a binary age category such as >60 years vs ≤60 years) (Table S4). Thirty-one studies were included in the meta-analysis. Six studies (27, 37, 58, 65, 67, 83) were excluded because of the use of a binary age category, while one was excluded because the risk was reported by an age z-score, making it hard to compare to the other studies (81). Four studies were excluded from the main meta-analysis because they investigated mortality only on critically-ill hospitalized patients or patients with COVID-19 cytokine storm (43, 50, 53, 72). Two studies (36, 56) investigated the same study population, but Carter and Collins et al. 2020 (36) was chosen because this study had adjusted for more age-related risk factors. Likewise, Shi et al. 2020 (84) and Zhao et al. 2020 (95) used the same population. The former study was used because it reported age as a continuous factor, rather than a very rough age category. For the studies using age as categorical variables, the age and log of RR were modeled as linear and cubic relationships and plotted (Figure S3). Although the weighted cubic model had a lower AIC value (-71.8) than the weighted linear model (-62.5), the cubic model showed no evidence of a rapid increase in the slope at a specific age. At around age 70, there was a downturn in the slope which did not follow the points, indicating a possible better fit with a fractional or higher-level polynomial relationship. We assumed a log-linear

relationship for simplicity, as at least for the ranges 20 to 70 years there seemed to be no conflict

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

with that assumption. A per-year effect was calculated for studies using age categories and they were included in the meta-analysis. The pooled RR for the 31 studies was 1.046 (95% CI: 1.039-1.054) per age year (Table 2). The funnel plot was asymmetric (Figure S4; Egger's test p<0.0001), but the funnel plot using age as a continuous variable differed from the one using age derived from categories (Figure S5a-b). Upon closer look, the pooled RR of studies using age as a continuous variable (16 studies, 52%) was higher than the pooled RR of studies dividing age into categories (RRage continuous = 1.057; 95% CI 1.047-1.067; RRage categories =1.037; 95% CI 1.028-1.046). Since the calculated midpoints from the age categories might be inaccurate, we hypothesized that the RR of studies using a higher number of age categories would be closer to the RR_{age continuous}. Indeed, studies having more than four age categories had a pooled RR of 1.039 (95% CI 1.026-1.053), whereas studies with four or less age categories had a pooled RR of 1.030 (95% CI 1.020-1.041). We divided studies by age category width (5 vs. 10 vs. 10+ years intervals) and found that the effect estimate was lowest with studies using the widest age categories (10+ years RR=1.030; 95% CI 1.021-1.039), followed by studies using 10-year categories (RR=1.046; 95% CI 1.040-1.051). Only one study used a 5-year age category, having the highest estimate (RR=1.060; 95%CI 1.051-1.070). Because of probable bias using different age categories, further analyses for in-hospital mortality focused on studies using age as a continuous variable (Table 2). The pooled RR did not differ by study quality. Studies from USA, Europe, and South Korea had similar pooled RRs, whereas as the pooled RR for the Chinese studies was lower (RR=1.041; 95% CI 0.999-1.085). The unadjusted and adjusted RRs on studies reporting both values were similar (RR_{unadiusted}=1.060, 95% CI: 1.034-1.086; RR_{adiusted}=1.059, 95% CI: 1.037-1.081).

Table 2. Results of pooled risks from meta-analyses

	Pooled ES (per age year)	Risk estimates (n)		
In-hospital mortality				
All studies	1.046 (1.038-1.054)	31	93.2%	
Age: continuous	1.057 (1.047-1.067)	16	64.1%	
Age: categories	1.037 (1.028-1.046)	15	94.9%	
Quality: high*	1.057 (1.045-1.070)	12	58.7%	
Quality: low*	1.057 (1.040-1.074)	4	77.7%	
Region: USA*	1.059 (1.045-1.072)	8	74.5%	
Region: Europe*	1.060 (1.044-1.077)	5	40.3%	
Region: China*	1.041 (0.999-1.085)	2	78.8%	
Region: South Korea*	1.055 (1.003-1.109)	1	-	
Case mortality				
All studies	1.074 (1.061-1.087)	11	85.3%	
Age: continuous	1.063 (1.043-1.084)	3	68.7%	
Age: categories	1.078 (1.059-1.097)	8	73.7%	
Quality: high	1.094 (1.082-1.106)	2	0%	
Quality: low	1.069 (1.056-1.083)	9	82.0%	
Region: USA	1.061 (1.048-1.073)	5	67.1%	
Region: Europe	1.100 (1.075-1.125)	3	76.6%	
Region: South Africa	1.072 (1.057-1.088)	1	=	
Region: South America	1.090 (1.058-1.122)	1	=	
Region: China	1.040 (1.015-1.065)	1	-	
Hospitalization				
All studies	1.034 (1.021-1.048)	11	99.9%	
Age: continuous	1.039 (1.016-1.062)	3	86.8%	
Age: categories	1.034 (1.018-1.049)	8	99.9%	
Quality: high	1.051 (1.040-1.061)	4	97.2%	
Quality: low	1.025 (1.019-1.032)	7	98.1%	
Region: USA	1.033 (1.025-1.042)	7	93.5%	
Region: Europe	1.047 (1.034-1.060)	3	98.2%	
Region: South America	1.016 (1.016-1.017)	1	-	
ICU admission				
All studies	1.006 (0.999-1.013)	8	51.2%	
Age: continuous	1.003 (0.996-1.010)	5	19.0%	
Age: categories	1.013 (0.998-1.028)	3	31.6%	
Quality: high	1.004 (0.996-1.013)	3	76.1%	
Quality: low	1.011 (0.996-1.026)	5	30.7%	
Region: USA	1.007 (1.000-1.013)	6	50.4%	
Region: China	1.033 (0.939-1.136)	2	74.9%	
Intubation				
All studies	1.006 (0.995-1.018)	6	74.8%	
Age: continuous	1.008 (0.992-1.024)	3	0.0%	
Age: categories	1.006 (0.991-1.021)	3	88.1%	

^{*}for age continuous; ES= effect size

234

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

Case Mortality Fourteen studies investigating case mortality were included, in which mortality was ascertained in individuals who had tested positive for COVID-19. Five studies were from USA (52, 54, 61, 90, 92), three studies originated from Europe (34, 78, 79), three from Latin America (35, 86, 87), and one each from China (51), South Africa (33), and South Korea (66). The results can be seen in Table S5. Three studies (21%) were rated as having a low risk of bias. Most of the studies had a high risk of bias because they did not adjust for all age-dependent risk factors, the age categories were quite wide, and the recruitment procedure indicated a possible selection bias (i.e. such as recruitment of only symptomatic people or people who presented for care at hospitals without being hospitalized, or if ICD codes used for recruitment were not necessarily related to COVID-19) (Table S6). Eleven studies were included in the meta-analysis, of which the majority used age categories (8 of 11). One study was excluded due to the use of binary age categories (87). One study (54) reported the age year RR within age categories, and therefore it was not possible to compare to the other studies. Two studies used the same study population (35, 86), but Solis et al. 2020 (86) was chosen because the study had adjusted for more age-related factors and it had used a higher number of age categories. The cubic model showed a relatively flat relationship between log(RR) and age from ages 40 to 85 years (Figure S6). Because both models had similar AIC values (linear: -157.4; cubic: -159.3), we assumed a linear model. The meta-analysis resulted in a pooled RR of 1.074 (95% CI 1.061-1.087) per age year (Table 4). The respective funnel plot showed asymmetry (Figure S7), although Egger's test was not significant (p=0.320). The pooled RR of studies using continuous (RR=1.063; 95% CI 1.043-1.084) and categorical (RR=1.078; 1.059-1.097) age variables differed. However, since the 95% CI values overlapped, there was no significant difference observed. We divided studies by age category width (5 vs. 10 vs. 10+year intervals) and again found that the effect estimate was lowest with studies using the widest age categories (10+ years RR=1.042; 95% CI 1.028-1.056; 10 years RR=1.080; 95% CI 1.057-1.103) and

highest for studies using the most narrow age of five years (RR=1.094; 95% CI 1.082-1.107).

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

The high-quality studies had a higher RR per age than low quality studies (RRhigh quality=1.094, 95% CI: 1.082-1.106; RR_{low quality}=1.069; 95% CI: 1.056-1.083). European studies (n=3) had the highest pooled RR (RR= 1.100; 95% CI 1.075-1.125), followed by USA studies (RR= 1.061; 95% CI 1.075-1.125). Other regions had only one study, so a reliable comparison was not possible. The unadjusted and adjusted RRs on studies reporting both values were similar (RR_{unadjusted}=1.079; 95% CI: 1.062-1.097; $RR_{adjusted}$ =1.072; 95% CI: 1.054-1.091). Hospitalization A summary of the results of studies investigating risk of hospitalization by age can be seen in Table S7. The study population typically used were individuals who were positive for COVID-19, some of which were hospitalized due to complications related to the infection. Sixteen studies were included, of which nine originated in the USA (29, 38, 47, 52, 63, 76, 77, 91, 96), three in Europe (34, 78, 79), three in Latin America (35, 49, 85), and one in Israel (70). Four (25%) of the studies had a low risk of bias, and the reasons for high risk of bias were mainly the lack of adjustment for all pre-defined agerelated risk factors and the use of binary or rough age categories (Table S8). Of the sixteen studies, eleven were included in the meta-analysis. Ebinger et al. 2020 (47) was excluded because the outcome was complex with reference categories that could not be compared to other studies (hospitalized/non-ICU vs. ICU/non-intubated vs ICU/intubated). Carrillo-Vega et al. 2020 (35) and Giannouchos et al. 2020 (49) used the same study population, but the latter was used because the study had more age categories and adjusted for a higher number of age-related risk factors. Furthermore, two studies (70, 85) used binary age categories and one did not provide confidence intervals (63). Most studies (8 of 11) used age categories. The results of the weighted linear and cubic models of studies using age categories are shown in Figure S8. Although the AIC values for the linear model were higher than for the cubic model (-57.2 vs -21.7, we did choose the linear model because of a lack of threshold where the rate increases with age and because the age range modeled appeared as a linear relationship.

ge and because the age range modeled appeared as a linear relationship.

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

The pooled RR for all studies was 1.034 (95% CI: 1.021-1.048). The funnel plot looked asymmetric (Figure S9), but Egger's test was statistically not-significant (p=0.439). The RR of studies using continuous and categorical age values were very similar (Table 4), noting that most studies (63%) using age categories utilized more than four age categories. Again, using a finer age width increased the RR for studies using age categories (10+ years RR=1.024 95% CI: 1.018-1.030; 10 years RR=1.040 95%CI: 1.037-1.043; 5 years RR=1.056 95% CI:1.055.1.057). The pooled effect for high-quality studies was higher than for low quality studies (RRhigh quality=1.051, 95% CI: 1.040-1.061; RRiow quality=1.025; 95% CI: 1.019-1.032). Moreover, the European studies had a higher pooled risk (RR=1.047; 95% CI: 1.034-1.060) than the USA studies (RR=1.033, 95% CI: 1.025-1.042), but the difference was not statistically significant. The unadjusted RR values were slightly higher than the adjusted values (RR_{unadiusted}=1.045, 95% CI: 1.026-1.065; RR_{adiusted}=1.031, 95% CI: 1.009-1.053). Admission to ICU Twelve studies investigated the effect of age on admission to ICU. Typically, the studies used hospitalized individuals as the study population and followed them up (retrospectively or prospectively). Eight studies originated in the USA (28, 55, 61, 64, 77, 82, 88, 96) and four were from China (32, 46, 51, 89). A summary of the results can be seen in Table S9. Four (33%) of the studies were of high quality (low risk of bias). Similar to the other outcomes, the reasons for a high risk of bias were mainly due to the confounding domain, and to a lesser extent, to the exposure domain (rough age categories) (Table S10). Eight studies were included in the meta-analysis. Du et al. 2020 (46) was not included. Due to the nature of its complex outcome, it could not be compared to other studies. Two studies evaluated the risk of ICU on individuals who had tested positive to COVID-19 (51, 96), and one study used a binary age category (88). The pooled RR for the studies was 1.006 (95% CI: 0.999-1.013). Five studies (63%) used age as a continuous variable, and these studies had only a slightly lower RR (1.003; 95% CI: 0.996-1.010) compared to the ones using age as a categorical value (RR=1.013; 95% CI: 0.998-1.028), but still the

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

effect was statistically not-significant for both. The high quality studies had a slightly lower RR than the low quality studies (RRhigh quality=1.004, 95% CI: 0.996-1.013; RRlow quality=1.011; 95% CI: 0.996-1.026), but again both estimates were not statistically-significant (Table 4). Mechanical ventilation (intubation) Seven studies investigated the effect of age on the risk of intubation, using individuals hospitalized due to COVID-19. All studies were set in the USA (42, 55, 74, 82, 88, 91), and a summary of the results can be seen in Table S11. No studies had a low risk of bias (high quality), either due to the "confounding" or "exposure assessment" domain (Table S12). Half of the studies used age categories, and the effect estimate was similar for studies using a continuous and a categorical age variable. One study (88) was excluded from the meta-analysis because it used a binary category for age. The pooled RR showed a very weak statistically not-significant increase in risk per age year (RR=1.006; 95% CI 0.995-1.018) (Table 4). Quality of evidence Since only observational studies were included, the initial level of evidence was set at "moderate". After decreasing a level for unclear publication bias, and increasing two levels for dose-response effect and two levels for a large effect estimate, the overall certainty of evidence was high for both risk of in-hospital mortality and case mortality. For hospitalization, after downgrading for high inconsistency and unclear publication bias, and upgrading for dose response, effect estimate, and effect size, the overall certainty of evidence was high (Table 5). There was no statistically-significant effect observed for admission to ICU and intubation. Hence, these outcomes were not included in the assessment.

Table 5. Assessment of evidence for the risk of studied outcomes based on Grades of Recommendations, Assessment, Development, and Evaluation framework (GRADE).

Risk	Quality of study limitations: ↓	Indirectness of evidence: ↓	Inconsistency:	Imprecision, range confidence interval effect size >2.0: ↓	Publication bias, yes or unclear: ↓	Effect estimate >2.0: ↑ >5.0: ↑↑	Dose- response effect: 个	Residual confounding: 个	Overall certainty (high, moderate, low)
In-hospital mortality	no (-) ¹	no (-)	no (-) ²	no (-)	unclear ↓	yes 个个 ³	yes 个	no (-)	high
Case mortality	no (-) ¹	no (-)	no (-) ⁴	no (-)	unclear ↓	yes ↑↑⁵	yes 个	no (-)	high
Hospitalization	no (-) ¹	no (-)	yes ↓ ⁶	no (-)	unclear ↓	yes 个个 [′]	yes 个	no (-)	high

338 339

¹ High quality studies also reported a significant association between age and risk of outcome.

² Moderate heterogeneity (l^2 =64.1%) was observed on studies using age as a continuous variable and on high-quality studies (l^2 = 58.7%)

³ Although per age RR is 1.057, when comparing different adult groups can have an effect size of greater than 5.0 (i.e., a 54-year difference, 18 years vs 72 years results in a RR of 20.0)

⁴ Moderate heterogeneity (|²=68.7%) was observed on studies using age as a continuous variable and on high-quality studies heterogeneity was very low (|²=0%)

⁵ Although per age RR is 1.074, when comparing different adult groups can have an effect size of greater than 5.0 (i.e., a 54-year difference, 18 years vs 72 years results in a RR of 47.2)

⁶ High heterogeneity observed (|² > 85%)

Although per age RR is 1.034, when comparing different adult groups can have an effect size of greater than 5.0 (i.e., a 54-year difference, 18 years vs 72 years results in a RR of 6.08)

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

Discussion An increased age-related risk of COVID-19 in-hospital mortality, case mortality, and hospitalization of 5.7%, 7.4%, and 3.4% per age year, respectively, was observed, with a high quality of evidence. Further, there was no evidence of an age threshold at which the risk of disease severity increased, with the age effect appearing to be linear. The association between age and both ICU admission and mechanical ventilation was weak and not statistically-significant. Although effects varied slightly by region, there were no obvious trends observed. Our results for case mortality are in agreement with a review which found a log-linear association between age and infection fatality rate, but which did not include comorbidities in their analysis (9). Strengths and limitations To our knowledge, since our rapid review published (13), this is the first systematic review primarily focused on estimating the isolated effect of age on the risk of COVID-19 disease severity, including case and in-hospital mortality, hospitalization, ICU admission, and intubation. It encompasses 70 primary studies with data from more than 400,000 participants and includes only studies adjusting for important age-related factors associated with COVID-19 disease severity (14). Adjusting for comorbidities allows to explicitly "factor out" the mediating effect of comorbidities in order to get the isolated effect of age, or the risk presented by a person of a given age who has no preexisting conditions. The results in this review should be considered in light of its limitations. For studies reporting age as a categorical value, since the age categories used in the studies could not be compared because of their heterogeneity, the median of the age category represented the age for the reported effect size. This procedure could have led to inaccuracies of the effect size. This was evident in that effect sizes increased when using finer age categories, indicating that the use of wide age categories most likely leads to an underestimation of the age effect. We reported the pooled effect sizes for studies using age as a continuous variable for the outcome in-hospital mortality. For the other outcomes we reported the pooled effect size for studies using categorical and continuous age variables together since their effect was similar.

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

The funnel plots were asymmetrical, which was especially obvious for in-hospital mortality, where half of the studies used age as a categorical variable. However, funnel plot asymmetry has other possible causes besides publication bias (97). In this case, we believe that the cause is due to the heterogeneity of the exposure-namely when using studies with age as categorical variables. This was indeed shown when plotting funnel plots separately for studies using continuous and categorical age variables. The studies using continuous variables did not show obvious asymmetry in the funnel plots, while the studies using categorical age variables did show asymmetry. However, they had a narrow range of standard errors, which is also a contraindication for using funnel plots (97, 98). Even though we downgraded for publication bias in our GRADE evaluation, the overall assessment of evidence was still rated as high. The adjusted effect estimates were only slightly lower than the unadjusted estimates, or at least the difference was not as great as observed in our previous rapid review. An explanation could be a potential interaction effect between age and certain chronic diseases, or a possible selection effect. This was observed in the related umbrella review by Treskova et al. 2021 (14) and the review by Mesas et al. 2021 (99) where younger individuals who had heart failure and kidney disease had a higher risk of in-hospital mortality compared to the risk observed in older individuals. This effect was also seen for hypertension (99). It may be that older patients are more quickly admitted to the hospital with less severe concomitant diseases than younger patients, which may be reflected as an increased in-hospital mortality for younger patients, essentially due to a selection effect in the hospital admission. There was no increased risk by age year for being admitted to the ICU or for mechanical ventilation, but this result is hard to reconcile, given the strength of association between age and mortality. The included studies mostly occurred during the first and second waves, when ICU capacity was limited. How this lack of association is due to the possibility of triage in some scenarios is unknown, but worth considering.

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

Lastly most of the primary studies included were done in the first or second wave of the pandemic, and new mutations which may affect the association between age and disease severity were not considered. Methodological quality of the included studies Although high-quality studies were present for every outcome except mechanical ventilation, lowquality studies dominated. High-quality studies had the same effect estimate as low-quality studies for in-hospital mortality, but for case mortality and hospitalization, low-quality studies underestimated the isolated effect of age. The main reason for a low risk of bias was the lack of adjustment for all age-related risk factors in the domain "confounding". Moreover, considering the "recruitment" domain, some studies included participants who used clinical symptoms as a COVID-19 case, which is less accurate than a RT-PCR test. It should be mentioned that the recruitment domain could have potentially been high risk for most studies, as in the early stages of the pandemic, RT-PCR testing was relatively scarce, and only individuals with symptoms or who had direct contact with a positive person were tested in some countries. Furthermore, some studies used rough age categories which will lead to an inaccurate risk effect. Lastly, some studies corrected for biomarkers or factors (such as fever, d-Dimer level, lymphocyte count) that reflect disease severity. When studying associations between disease severity and age and chronic factors, using such markers in the model should be avoided to avoid overadjustment. Implications for practice, policy, and future research During the COVID-19 pandemic, it is necessary to accurately define risk groups for COVID-19 disease severity when implementing contact or work restrictions. This review shows that increased age year is associated with mortality and hospitalization, and an age threshold for which there is a marked increase in risk was not apparent. Therefore, targetting persons above a certain (arbitrary) age threshold is not recommended in the workplace, as it may lead to ageism, permeating in the community and in the workplace (100). If workers older than 60 years are not allowed to perform a work task because of perceived higher risk of disease severity starting at that age, it is difficult to argue why a person can still perform that activity at age 59, but must stop it or needs special

protection on their 60th birthday. Rather, individualized risk profiles should be made by considering a continuous increase in risk by age-year. Contrary to workplace restrictions, the use of an isolated, per-age year increase when prioritizing vaccinations is not recommended. Government agencies often divide the population in age groupsbut this categorization is not purely about age-related effects. Rather, the high-age groups always include a higher proportion of individuals with pre-exisiting conditions. In this respect, our result of an approximately linear increase in isolated age risk cannot be used as an argument against the definition of vaccination prioritization groups. This comprehensive review contradicts our previous rapid review (13), which encompassed mainly Chinese studies and indicated a weak influence of age on COVID-19 disease severity. This highlights the need for continuous, "living" reviews of the available evidence throughout the pandemic, as results may change due to more available evidence available or to new variants affecting the association between age and disease severity. Further, as there are hints of possible effect modifications between age and certain chronic diseases (14), future studies should focus on quantifying these interactions. **Conclusions** A best-possible quantification of the increase in COVID-19 disease severity due to age was achieved. Age-related workplace prevention programs should consider the continuous increase in risk, rather than implementing age thresholds. There is a need for continuous, high-quality research to characterize age associations with disease severity in light of new variants. Acknowledgments Our heartfelt thanks to Dr. Thomas Harder and Dr. Marina Treskova from the Robert Koch Institute for their recommendations and for giving us access to their study database.

Patient and Public Involvement

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

- Patients or the public were not involved in the design, or conduct, or reporting, or dissemination
- 448 plans of our research.

449 References

- 451 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with
- 452 Pneumonia in China, 2019. New England Journal of Medicine. 2020;382(8):727-33.
- 453 2. WHO. Coronavirus disease (COVID-19) pandemic, 2021 2021 [Available from:
- 454 https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
- 455 3. Chen T, Dai Z, Mo P, Li X, Ma Z, Song S, et al. Clinical characteristics and outcomes of older
- 456 patients with coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): a single-centered,
- retrospective study. J Gerontol A Biol Sci Med Sci. 2020:glaa089.
- 458 4. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased
- patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091.
- 460 5. Dudley JP, Lee NT. Disparities in Age-specific Morbidity and Mortality From SARS-CoV-2 in
- 461 China and the Republic of Korea. Clin Infect Dis. 2020.
- 462 6. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity
- of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020:S1473-3099(20)30243-7.
- 464 7. Robert Koch Institut (RKI). Informationen und Hilfestellungen für Personen mit einem
- 465 höheren Risiko für einen schweren COVID-19-Krankheitsverlauf 2010 [updated 05/28/2020. Available
- from: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Risikogruppen.html.
- 467 8. CDC. Underlying medical conditions associated with high risk for severe COVID-19:
- Information for healthcare providers. National Center for Immunization and Respiratory Diseases
- 469 (NCIRD), Division of Viral Diseases; 2021 March 29, 2021.
- 470 9. Levin AT, Hanage WP, Owusu-Boaitey N, Cochran KB, Walsh SP, Meyerowitz-Katz G.
- 471 Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-
- analysis, and public policy implications. European Journal of Epidemiology. 2020;35(12):1123-38.
- 473 10. Robert Koch Institut (RKI). Todesfälle nach Sterbedatum (2.4.2021).
- 474 https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Projekte_RKI/COVID-
- 475 19 Todesfaelle.html: RKI; 2021.
- 476 11. Wolfschmidt A, Ochmann U, Nowak D, Drexler H. Schwerpunkt-Themen.
- 477 12. Kaifie A, Starke KR, Kämpf D, Tautz A, Petereit-Haack G, Angerer P, et al. Schwerpunkt-
- 478 Themen.

- 479 13. Romero Starke K, Petereit-Haack G, Schubert M, Kämpf D, Schliebner A, Hegewald J, et al.
- 480 The Age-Related Risk of Severe Outcomes Due to COVID-19 Infection: A Rapid Review, Meta-Analysis,
- 481 and Meta-Regression. International Journal of Environmental Research and Public Health.
- 482 2020;17(16):5974.
- 483 14. Treskova-Schwarzbach M, Haas L, Reda S, Pilic A, Borodova A, Karimi K, et al. Pre-Existing
- 484 Health Conditions and Severe COVID-19 Outcomes: Umbrella Review and Meta-Analysis of Global
- 485 Evidence. SSRN; 2021.
- 486 15. Ijaz S, Verbeek J, Seidler A, Lindbohm ML, Ojajärvi A, Orsini N, et al. Night-shift work and
- breast cancer--a systematic review and meta-analysis. Scand J Work Environ Health. 2013;39(5):431-
- 488 47.
- 489 16. Johnson PI, Koustas E, Vesterinen HM, Sutton P, Atchley DS, Kim AN, et al. Application of the
- 490 Navigation Guide systematic review methodology to the evidence for developmental and
- reproductive toxicity of triclosan. Environment international. 2016;92:716-28.
- 492 17. Scottish Intercollegiate Guidelines Network (SIGN). Methodology checklist 3: cohort studies
- 493 Edinburgh: SIGN; [updated 30.05.2018. Available from: http://www.sign.ac.uk.
- 494 18. Critical Appraisal Skills Programme. CASP Cohort Study Checklist 2018 [Available from:
- 495 https://casp-uk.net/casp-tools-checklists/.
- 496 19. Orsini N, Bellocco R, Greenland S. Generalized least squares for trend estimation of
- 497 summarized dose-response data. The stata journal. 2006;6(1):40-57.
- 498 20. Harris RJ, Deeks JJ, Altman DG, Bradburn MJ, Harbord RM, Sterne JA. Metan: fixed-and
- random-effects meta-analysis. The Stata Journal. 2008;8(1):3-28.

- 500 21. Seidler A, Romero Starke K, Freiberg A, Hegewald J, Nienhaus A, Bolm-Audorff U. Dose-
- 501 Response Relationship between Physical Workload and Specific Shoulder Diseases—A Systematic
- 502 Review with Meta-Analysis. International Journal of Environmental Research and Public Health.
- 503 2020;17(4):1243.
- 504 22. Zhang J, Kai FY. What's the relative risk?: A method of correcting the odds ratio in cohort
- studies of common outcomes. Jama. 1998;280(19):1690-1.
- 506 23. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1.
- 507 Introduction—GRADE evidence profiles and summary of findings tables. Journal of clinical
- 508 epidemiology. 2011;64(4):383-94.
- 509 24. Hulshof CT, Colosio C, Daams JG, Ivanov ID, Prakash K, Kuijer PP, et al. WHO/ILO work-related
- 510 burden of disease and injury: Protocol for systematic reviews of exposure to occupational ergonomic
- risk factors and of the effect of exposure to occupational ergonomic risk factors on osteoarthritis of
- 512 hip or knee and selected other musculoskeletal diseases. Environment international. 2019;125:554-
- 513 66.
- 514 25. Petereit-Haack G, Bolm-Audorff U, Romero Starke K, Seidler A. Occupational Risk for Post-
- 515 Traumatic Stress Disorder and Trauma-Related Depression: A Systematic Review with Meta-Analysis.
- International Journal of Environmental Research and Public Health. 2020;17(24):9369.
- 517 26. Zijdeman R, Ribeira da Silva F. Life Expectancy at Birth (Total). V1 ed: IISH Data Collection;
- 518 2015.
- 519 27. Antwi-Amoabeng D, Beutler B, Awad M, Kanji Z, Mahboob S, Ghuman J, et al.
- 520 Sociodemographic predictors of outcomes in COVID-19: examining the impact of ethnic disparities in
- 521 Northern Nevada. medRxiv. 2020.
- 522 28. Argenziano M, Bruce S, Slater C. Characterization and Clinical Course of 1000 Patients with
- 523 COVID-19 in New York: retrospective case series. medRxiv. 2020:10.1101.
- 524 29. Azar KMJ, Shen Z, Romanelli RJ, Lockhart SH, Smits K, Robinson S, et al. Disparities In
- 525 Outcomes Among COVID-19 Patients In A Large Health Care System In California. Health Aff
- 526 (Millwood). 2020;39(7):1253-62.
- 527 30. Baqui P, Bica I, Marra V, Ercole A, van der Schaar M. Ethnic and regional variations in hospital
- mortality from COVID-19 in Brazil: a cross-sectional observational study. Lancet Glob Health.
- 529 2020;8(8):e1018-e26.
- 530 31. Bello-Chavolla OY, Bahena-López JP, Antonio-Villa NE, Vargas-Vázquez A, González-Díaz A,
- 531 Márquez-Salinas A, et al. Predicting Mortality Due to SARS-CoV-2: A Mechanistic Score Relating
- 532 Obesity and Diabetes to COVID-19 Outcomes in Mexico. The Journal of clinical endocrinology and
- 533 metabolism. 2020;105(8):dgaa346.
- 534 32. Bi Q, Hong C, Meng J, Wu Z, Zhou P, Ye C, et al. Characterizing clinical progression of COVID-
- 19 among patients in Shenzhen, China: an observational cohort study. medRxiv.
- 536 2020:2020.04.22.20076190.
- 537 33. Boulle A, Davies M-A, Hussey H, Ismail M, Morden E, Vundle Z, et al. Risk factors for COVID-
- 538 19 death in a population cohort study from the Western Cape Province, South Africa. Clinical
- 539 infectious diseases : an official publication of the Infectious Diseases Society of America.
- 540 2020:ciaa1198.
- 541 34. Burn E, Tebe C, Fernandez-Bertolin S, Aragon M, Recalde M, Roel E, et al. The natural history
- of symptomatic COVID-19 in Catalonia, Spain: a multi-state model including 109,367 outpatient
- diagnoses, 18,019 hospitalisations, and 5,585 COVID-19 deaths among 5,627,520 people. medRxiv.
- 544 2020:2020.07.13.20152454.
- 545 35. Carrillo-Vega MF, Salinas-Escudero G, García-Peña C, Gutiérrez-Robledo LM, Parra-Rodríguez
- L. Early estimation of the risk factors for hospitalization and mortality by COVID-19 in Mexico. PLOS
- 547 ONE. 2020:15(9):e0238905.
- 548 36. Carter B, Collins JT, Barlow-Pay F, Rickard F, Bruce E, Verduri A, et al. Nosocomial COVID-19
- 549 infection: examining the risk of mortality. The COPE-Nosocomial Study (COVID in Older PEople). The
- 550 Journal of hospital infection. 2020;106(2):376-84.

- 551 37. Chen J, Bai H, Liu J, Chen G, Liao Q, Yang J, et al. Distinct Clinical Characteristics and Risk
- 552 Factors for Mortality in Female Inpatients With Coronavirus Disease 2019 (COVID-19): A Sex-
- 553 stratified, Large-scale Cohort Study in Wuhan, China. Clinical Infectious Diseases. 2020.
- 554 38. Chhiba KD, Patel GB, Vu THT, Chen MM, Guo A, Kudlaty E, et al. Prevalence and
- characterization of asthma in hospitalized and nonhospitalized patients with COVID-19. J Allergy Clin
- 556 Immunol. 2020;146(2):307-14.e4.
- 557 39. Chilimuri S, Sun H, Alemam A, Mantri N, Shehi E, Tejada J, et al. Predictors of Mortality in
- 558 Adults Admitted with COVID-19: Retrospective Cohort Study from New York City. West J Emerg Med.
- 559 2020;21(4):779-84.
- 560 40. Ciardullo S, Zerbini F, Perra S, Muraca E, Cannistraci R, Lauriola M, et al. Impact of diabetes
- on COVID-19-related in-hospital mortality: a retrospective study from Northern Italy. J Endocrinol
- 562 Invest. 2020.
- 563 41. Conversano A, Melillo F, Napolano A, Fominskiy E, Spessot M, Ciceri F, et al. Renin-
- 564 Angiotensin-Aldosterone System Inhibitors and Outcome in Patients With SARS-CoV-2 Pneumonia: A
- 565 Case Series Study. Hypertension. 2020;76(2):e10-e2.
- 566 42. Costa Monteiro AC, Suri R, Emeruwa IO, Stretch RJ, Cortes Lopez RY, Sherman A, et al.
- 567 Obesity and Smoking as Risk Factors for Invasive Mechanical Ventilation in COVID-19: a
- 568 Retrospective, Observational Cohort Study. medRxiv. 2020:2020.08.12.20173849.
- 569 43. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al.
- 570 Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a
- 571 prospective cohort study. Lancet. 2020.
- 572 44. Di Castelnuovo A, Bonaccio M, Costanzo S, Gialluisi A, Antinori A, Berselli N, et al. Common
- cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis
- and machine learning-based findings from the multicentre Italian CORIST Study. Nutr Metab
- 575 Cardiovasc Dis. 2020;30(11):1899-913.
- 576 45. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20
- 577 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol:
- 578 prospective observational cohort study. Bmj. 2020;369:m1985.
- 579 46. Du R, Liang L, Yang C, Li M, Guo G, van Halm-Lutterodt N, et al. Patient Predisposition at
- 580 Hospital Admission Indirectly Dictates Disease Severity, Clinical Course and Outcomes of COVID-19
- 581 Pneumonia Patients in Wuhan, China. SSRN. 2020.
- 582 47. Ebinger JE, Achamallah N, Ji H, Claggett BL, Sun N, Botting P, et al. Pre-existing traits
- associated with Covid-19 illness severity. PloS one. 2020;15(7):e0236240-e.
- 584 48. Giacomelli A, Ridolfo AL, Milazzo L, Oreni L, Bernacchia D, Siano M, et al. 30-day mortality in
- 585 patients hospitalized with COVID-19 during the first wave of the Italian epidemic: A prospective
- cohort study. Pharmacological Research. 2020;158:104931.
- 587 49. Giannouchos TV, Sussman RA, Mier JM, Poulas K, Farsalinos K. Characteristics and risk factors
- 588 for COVID-19 diagnosis and adverse outcomes in Mexico: an analysis of 89,756 laboratory-confirmed
- 589 COVID-19 cases. Eur Respir J. 2020.
- 590 50. Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al. Risk Factors
- 591 Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy.
- 592 JAMA Intern Med. 2020;180(10):1345-55.
- 593 51. Gu T, Chu Q, Yu Z, Fa B, Li A, Xu L, et al. History of coronary heart disease increased the
- mortality rate of patients with COVID-19: a nested case–control study. BMJ Open.
- 595 2020;10(9):e038976.
- 596 52. Gu T, Mack JA, Salvatore M, Prabhu Sankar S, Valley TS, Singh K, et al. Characteristics
- 597 Associated With Racial/Ethnic Disparities in COVID-19 Outcomes in an Academic Health Care System.
- 598 JAMA Network Open. 2020;3(10):e2025197-e.
- 599 53. Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, et al. Factors Associated
- With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US. JAMA Intern Med.
- 601 2020;180(11):1-12.

- 602 54. Harrison SL, Fazio-Eynullayeva E, Lane DA, Underhill P, Lip GYH. Comorbidities associated
- with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical
- 604 record analysis. PLOS Medicine. 2020;17(9):e1003321.
- 605 55. Hashemi N, Viveiros K, Redd WD, Zhou JC, McCarty TR, Bazarbashi AN, et al. Impact of
- 606 chronic liver disease on outcomes of hospitalized patients with COVID-19: A multicentre United
- States experience. Liver international: official journal of the International Association for the Study
- 608 of the Liver. 2020;40(10):2515-21.
- 609 56. Hewitt J, Carter B, Vilches-Moraga A, Quinn TJ, Braude P, Verduri A, et al. The effect of frailty
- on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study.
- 611 The Lancet Public Health. 2020;5(8):e444-e51.
- 612 57. Hwang J-M, Kim J-H, Park J-S, Chang MC, Park D. Neurological diseases as mortality predictive
- 613 factors for patients with COVID-19: a retrospective cohort study. Neurological sciences: official
- journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology.
- 615 2020;41(9):2317-24.
- 616 58. Imam Z, Odish F, Gill I, O'Connor D, Armstrong J, Vanood A, et al. Older age and comorbidity
- are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United
- 618 States. J Intern Med. 2020;288(4):469-76.
- 619 59. Jun T, Nirenberg S, Kovatch P, Huang K-l. Sex-specificity of mortality risk factors among
- 620 hospitalized COVID-19 patients in New York City: prospective cohort study. medRxiv.
- 621 2020:2020.07.29.20164640.
- 622 60. Kabarriti R, Brodin NP, Maron MI, Guha C, Kalnicki S, Garg MK, et al. Association of Race and
- 623 Ethnicity With Comorbidities and Survival Among Patients With COVID-19 at an Urban Medical
- 624 Center in New York. JAMA Network Open. 2020;3(9):e2019795-e.
- 625 61. Kalligeros M, Shehadeh F, Mylona EK, Benitez G, Beckwith CG, Chan PA, et al. Association of
- 626 Obesity with Disease Severity Among Patients with Coronavirus Disease 2019. Obesity.
- 627 2020;28(7):1200-4.
- 628 62. Khalil K, Agbontaen K, McNally D, Love A, Mandalia S, Banya W, et al. Clinical characteristics
- 629 and 28-day mortality of medical patients admitted with COVID-19 to a central London teaching
- hospital. The Journal of infection. 2020;81(3):e85-e9.
- 63. Killerby M, Link-Gelles R, Haight S, Schrodt C, England L, Gomes D, et al. Characteristics
- 632 Associated with Hospitalization Among Patients with COVID-19 Metropolitan Atlanta, Georgia,
- 633 March-April 2020. MMWR Morbidity and Mortality Weekly Report. 2020;69.
- 634 64. Kim L, Garg S, O'Halloran A, Whitaker M, Pham H, Anderson EJ, et al. Risk Factors for
- 635 Intensive Care Unit Admission and In-hospital Mortality Among Hospitalized Adults Identified
- 636 through the US Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance
- 637 Network (COVID-NET). Clinical Infectious Diseases. 2020.
- 638 65. Klang E, Kassim G, Soffer S, Freeman R, Levin MA, Reich DL. Severe Obesity as an
- 639 Independent Risk Factor for COVID-19 Mortality in Hospitalized Patients Younger than 50. Obesity
- 640 (Silver Spring). 2020.
- 64. Lee H-Y, Ahn J, Kang CK, Won S-H, Park J-H, Kang C, et al. Association of Angiotensin II
- 642 Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors on COVID-19-Related Outcome.
- 643 SSRN Electronic Journal. 2020.
- 644 67. Li J, Guo T, Dong D, Zhang X, Chen X, Feng Y, et al. Defining heart disease risk for death in
- 645 COVID-19 infection. QJM: An International Journal of Medicine. 2020.
- 646 68. Magleby R, Westblade LF, Trzebucki A, Simon MS, Rajan M, Park J, et al. Impact of SARS-CoV-
- 647 2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients with Coronavirus
- Disease 2019. Clinical infectious diseases: an official publication of the Infectious Diseases Society of
- 649 America, 2020:ciaa851.
- 650 69. Meng Y, Lu W, Guo E, Liu J, Yang B, Wu P, et al. Cancer history is an independent risk factor
- 651 for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis. Journal of
- 652 Hematology & Oncology. 2020;13(1):75.

- 653 70. Merzon E, Tworowski D, Gorohovski A, Vinker S, Golan Cohen A, Green I, et al. Low plasma
- 654 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-
- based study. The FEBS journal. 2020:10.1111/febs.15495.
- 656 71. Murillo-Zamora E, Hernandez-Suarez CM. Survival in adult inpatients with COVID-19. Public
- 657 Health. 2020.
- 658 72. Narain S, Stefanov DG, Chau AS, Weber AG, Marder G, Kaplan B, et al. Comparative Survival
- 659 Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm. Chest.
- 660 2020:S0012-3692(20)34901-1.
- 73. Palaiodimos L, Kokkinidis DG, Li W, Karamanis D, Ognibene J, Arora S, et al. Severe obesity,
- 662 increasing age and male sex are independently associated with worse in-hospital outcomes, and
- higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York.
- 664 Metabolism. 2020;108:154262.
- 665 74. Patel NG, Bhasin A, Feinglass JM, Belknap SM, Angarone MP, Cohen ER, et al. Clinical
- 666 Outcomes of Hospitalized Patients with COVID-19 on Therapeutic Anticoagulants. medRxiv.
- 667 2020:2020.08.22.20179911.
- 668 75. Perez-Guzman PN, Daunt A, Mukherjee S, Crook P, Forlano R, Kont MD, et al. Clinical
- 669 characteristics and predictors of outcomes of hospitalized patients with COVID-19 in a multi-ethnic
- 670 London NHS Trust: a retrospective cohort study. Clin Infect Dis. 2020.
- 671 76. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, et al. Factors associated
- 672 with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New
- York City: prospective cohort study. Bmj. 2020;369:m1966.
- 674 77. Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and Mortality among Black
- Patients and White Patients with Covid-19. N Engl J Med. 2020.
- 676 78. Reilev M, Kristensen KB, Pottegård A, Lund LC, Hallas J, Ernst MT, et al. Characteristics and
- 677 predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-
- 678 CoV-2 in Denmark: a nationwide cohort. International journal of epidemiology. 2020:dyaa140.
- 679 79. Rossi PG, Marino M, Formisano D, Venturelli F, Vicentini M, Grilli R. Characteristics and
- outcomes of a cohort of SARS-CoV-2 patients in the Province of Reggio Emilia, Italy, medRxiv.
- 681 2020:2020.04.13.20063545.
- 682 80. Salacup G, Lo KB, Gul F, Peterson E, De Joy R, Bhargav R, et al. Characteristics and clinical
- outcomes of COVID-19 patients in an underserved-inner city population: A single tertiary center
- 684 cohort. Journal of Medical Virology. 2020; n/a(n/a).
- 685 81. Sapey E, Gallier S, Mainey C, Nightingale P, McNulty D, Crothers H, et al. Ethnicity and risk of
- death in patients hospitalised for COVID-19 infection in the UK: an observational cohort study in an
- urban catchment area. BMJ Open Respiratory Research. 2020;7(1):e000644.
- 688 82. Seiglie J, Platt J, Cromer SJ, Bunda B, Foulkes AS, Bassett IV, et al. Diabetes as a Risk Factor for
- 689 Poor Early Outcomes in Patients Hospitalized With COVID-19. Diabetes Care. 2020;43(12):2938-44.
- 690 83. Shah P, Owens J, Franklin J, Mehta A, Heymann W, Sewell W, et al. Demographics,
- comorbidities and outcomes in hospitalized Covid-19 patients in rural southwest Georgia. Ann Med.
- 692 2020;52(7):354-60.
- 693 84. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of Cardiac Injury With Mortality in
- Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiology. 2020.
- 695 85. Soares RdCM, Mattos LR, Raposo LM. Risk Factors for Hospitalization and Mortality due to
- 696 COVID-19 in Espírito Santo State, Brazil. The American journal of tropical medicine and hygiene.
- 697 2020;103(3):1184-90.
- 698 86. Solís P, Carreňo H. COVID-19 Fatality and Comorbidity Risk Factors among Diagnosed Patients
- 699 in Mexico. medRxiv. 2020.
- 700 87. Sousa GJB, Garces TS, Cestari VRF, Florêncio RS, Moreira TMM, Pereira MLD. Mortality and
- 701 survival of COVID-19. Epidemiol Infect. 2020;148:e123.
- 702 88. Suleyman G, Fadel RA, Malette KM, Hammond C, Abdulla H, Entz A, et al. Clinical
- 703 Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in
- 704 Metropolitan Detroit. JAMA network open. 2020;3(6):e2012270-e.

- 705 89. Tai S, Tang J, Yu B, Tang L, Wang Y, Zhang H, et al. Association between Cardiovascular
- 706 Burden and Requirement of Intensive Care among Patients with Mild COVID-19. Cardiovascular
- 707 Therapeutics. 2020;2020:9059562.
- 708 90. Tartof SY, Qian L, Hong V, Wei R, Nadjafi RF, Fischer H, et al. Obesity and Mortality Among
- 709 Patients Diagnosed With COVID-19: Results From an Integrated Health Care Organization. Annals of
- 710 internal medicine. 2020;173(10):773-81.
- 711 91. van Gerwen M, Alsen M, Little C, Barlow J, Genden E, Naymagon L, et al. Risk factors and
- 712 outcomes of COVID-19 in New York City; a retrospective cohort study. J Med Virol. 2020.
- 713 92. Wang A-L, Zhong X, Hurd Y. Comorbidity and Sociodemographic determinants in COVID-19
- 714 Mortality in an US Urban Healthcare System. medRxiv. 2020:2020.06.11.20128926.
- 715 93. Wang L, He W, Yu X, Hu D, Bao M, Liu H, et al. Coronavirus disease 2019 in elderly patients:
- 716 Characteristics and prognostic factors based on 4-week follow-up. J Infect. 2020;80(6):639-45.
- 717 94. Yehia BR, Winegar A, Fogel R, Fakih M, Ottenbacher A, Jesser C, et al. Association of Race
- 718 With Mortality Among Patients Hospitalized With Coronavirus Disease 2019 (COVID-19) at 92 US
- 719 Hospitals. JAMA network open. 2020;3(8):e2018039-e.
- 720 95. Zhao M, Wang M, Zhang J, Gu J, Zhang P, Xu Y, et al. Comparison of clinical characteristics
- 721 and outcomes of patients with coronavirus disease 2019 at different ages. Aging. 2020;12(11):10070-
- 722 86.
- 723 96. Rentsch CT, Kidwai-Khan F, Tate JP, Park LS, King JT, Skanderson M, et al. Covid-19 Testing,
- 724 Hospital Admission, and Intensive Care Among 2,026,227 United States Veterans Aged 54-75 Years.
- 725 medRxiv. 2020:2020.04.09.20059964.
- 726 97. Sterne JAC, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, Lau J, et al. Recommendations for
- 727 examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials.
- 728 BMJ. 2011;343:d4002.
- 729 98. Page M, Higgins J, Sterne J. Chapter 13: Assessing risk of bias due to missing results in
- 730 synthesis. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.2 ed: Cochrane;
- 731 2021.
- 732 99. Mesas AE, Cavero-Redondo I, Álvarez-Bueno C, Sarriá Cabrera MA, Maffei de Andrade S,
- 733 Sequí-Dominguez I, et al. Predictors of in-hospital COVID-19 mortality: A comprehensive systematic
- 734 review and meta-analysis exploring differences by age, sex and health conditions. PLoS One.
- 735 2020;15(11):e0241742.
- 736 100. Monahan C, Macdonald J, Lytle A, Apriceno M, Levy SR. COVID-19 and ageism: How positive
- 737 and negative responses impact older adults and society. American Psychologist. 2020;75(7):887-96.

